Biology subjects

Hull, C. M.

Publications and source records attributed to Hull, C. M..

5 recordsLinked to original sources

bioRxiv2026

Inhibitors of spore germination act against diverse human fungal pathogens

Current antifungal drugs often cause severe side effects due to the conservation of molecular targets between fungal and mammalian cells. One way to avoid host toxicity in future antifungals is to leverage molecules with targets involved in processes unique to fungi, such as spore germination. Germination is conserved in several of the most critical fungal pathogens but absent in mammalian cells. In this work we evaluated 191 small molecule inhibitors of Cryptococcus germination for their abilities to inhibit germination of another fungal pathogen, Aspergillus fumigatus, as well as yeast growth of Candida albicans and a pan-resistant isolate of Candida (Candidozyma) auris. The cytotoxicity of these inhibitors towards human hepatocytes and erythrocytes was also assessed. Overall, we identified 101 molecules that were either 1) germination-specific inhibitors in one or both germinating species tested, or 2) inhibitory to both germination and vegetative growth in one or more species tested. The majority of these molecules exhibited minimal toxicity to the human cell types tested. Molecules were scored and ranked for therapeutic potential based on assay data. For two key molecules of interest, predicted binding targets (histone deacetylase and acetyl-CoA carboxylase) were identified computationally. Overall, the inhibitor molecules characterized here showed activity against phylogenetically diverse human fungal pathogens with minimal toxic effects on human cell lines.

microbiology↗

bioRxiv2025

The pre-mRNA Splicing Modulator Pladienolide B Inhibits Cryptococcus neoformans Germination and Growth

Cryptococcus neoformans is an opportunistic fungal pathogen responsible for life-threatening infections, particularly in immunocompromised individuals. The limitations of current antifungal therapies due to toxicity and the emergence of resistance highlight the need for novel treatment strategies and targets. C. neoformans has an intron-rich genome, and pre-mRNA splicing is required for expression of the vast majority of its genes. In this study, we investigated the efficacy of a human splicing inhibitor, pladienolide B (PladB), as an antifungal against C. neoformans. PladB inhibited growth of C. neoformans in liquid culture and spore germination. The potency of PladB could be increased by simultaneous treatment with either FK506 or clorgyline. This combination treatment resulted in significant reductions in fungal growth and prevented spore germination. Transcriptomic analysis revealed that PladB inhibits splicing in C. neoformans and results in wide-spread intron retention. In combination with FK506, this resulted in down-regulation of or intron-retention in transcripts from processes vital for cellular growth including translation, transcription, and RNA processing. Together, these results suggest that targeting RNA splicing pathways could be a promising antifungal strategy and that the effectiveness of splicing inhibitors as antifungals can be increased by co-administering drugs such as FK506. IMPORTANCEFungal infections, like those caused by Cryptococcus neoformans, can turn deadly for many patients. New treatments and therapeutic targets are needed to combat these pathogens. One potential target is the pre-mRNA processing pathway which is required for expression of nearly all protein-coding genes in C. neoformans. We have determined that a pre-mRNA splicing inhibitor can inhibit both C. neoformans growth and germination and that the potency of this drug can be increased when used in combination with other molecules. This work provides evidence that targeting steps in pre-mRNA processing may be an effective antifungal strategy and avenue for development of new medicines.

microbiology↗

bioRxiv2023

Spores of the fungal pathogen Cryptococcus exhibit cell type-specific carbon source utilization during germination

Spores are critical morphotypes required for long-term survival of most fungi. Under the right environmental conditions, spores can escape dormancy and differentiate into vegetatively growing cells through the process of germination. For fatal human fungal pathogens like Cryptococcus, germination is the key differentiation process required for spores to initiate vegetative growth and ultimately cause disease; however, relatively little is known about the molecular mechanisms that control germination. To this end, we performed an extensive characterization of Cryptococcus spore germination through the morphological assessment of germinating spores, the inhibition of key eukaryotic processes, and the detailed quantification of fungal spore germination kinetics under numerous nutrient conditions. We identified temporal associations between molecular and morphological events and determined that carbon metabolism pathways (both glycolysis and oxidative phosphorylation) were required from the beginning of germination. We further determined that carbon sources are primarily used as fuel rather than as simply triggers of germination commitment, and identified spore-specific carbon source utilization that is absent in yeast. Finally, we discovered the first spore-specific enzyme, Nth2, a trehalase that is required for germination when trehalose is the primary available carbon source. Together this work provides an extensive characterization of Cryptococcus spore germination and suggests that germination is more than simply a modified cell cycle but is rather a highly adapted differentiation process.

microbiology↗

bioRxiv2023

A Single Laccase Acts as a Key Component of Environmental Sensing in a Broad Host Range Fungal Pathogen

Secreted laccases are important enzymes on an ecological scale for their role in mediating plant-fungal interactions, but their function in fungal pathogenesis has yet to be elucidated. Ascomycete laccases have been primarily associated with cell wall melanin deposition, and laccase mutants in ascomycete species often demonstrate reduced pigmentation. In this study, a putatively secreted laccase, Sslac2, was characterized from the broad host-range plant pathogen Sclerotinia sclerotiorum, which is largely unpigmented and is not dependent on melanogenesis for plant infection. Of the seven putative laccases in the S. sclerotiorum genome, Sslac2 was the only one found to be highly upregulated during pathogenesis of soybeans and was additionally found to be induced during growth on solid surfaces. Gene knockouts of Sslac2 demonstrate wide ranging developmental defects, including abolished sclerotial formation, and are functionally non-pathogenic on unwounded tissue. While these mutants demonstrated a clear radial growth defect, enhanced growth was observed in liquid culture, likely due to altered hydrophobicity and thigmotropic responsiveness. Sslac2 mutants were also unable to respond to a host environment, and accordingly unable to differentiate penetration structures, respond appropriately to chemical stress, or produce the key virulence factor oxalic acid. Transmission and scanning electron microscopy of WT and mutant strains show apparent differences in extracellular matrix structure that may explain the inability of the mutant to respond to environmental cues. Targeting Sslac2 using host-induced gene silencing significantly improved resistance to S. sclerotiorum, suggesting that fungal laccases could be a valuable target of disease control. Collectively, we identified a laccase critical to the development and virulence of the broad host-range pathogen S. sclerotiorum and propose a potentially novel role for fungal laccases in modulating environmental sensing.

microbiology↗

bioRxiv2021

Discovery of fungal-specific targets and inhibitors using chemical phenotyping of pathogenic spore germination

There is a critical need for new antifungal drugs; however, the lack of available fungal-specific targets is a major hurdle in the development of antifungal therapeutics. Spore germination is a differentiation process absent in humans that could harbor uncharacterized fungal-specific targets. To capitalize on this possibility, we developed novel phenotypic assays to identify and characterize inhibitors of spore germination of the human fungal pathogen Cryptococcus. Using these assays, we carried out a high throughput screen of ~75,000 drug-like small molecules and identified and characterized 191 novel inhibitors of spore germination, many of which also inhibited yeast replication and demonstrated low cytotoxicity against mammalian cells. Using an automated, microscopy-based, quantitative germination assay (QGA), we discovered that germinating spore populations can exhibit unique phenotypes in response to chemical inhibitors. Through the characterization of these spore population dynamics in the presence of the newly identified inhibitors, we classified 6 distinct phenotypes based on differences in germination synchronicity, germination rates, and overall population behavior. Similar chemical phenotypes were induced by inhibitors that targeted the same cellular function or had shared substructures. Leveraging these features, we used QGAs to identify outliers among compounds that fell into similar structural groups and thus refined relevant structural moieties, facilitating target identification. This approach led to the identification of complex II of the electron transport chain as the putative target of a promising structural cluster of germination inhibitory compounds. These inhibitors showed high potency against Cryptococcus spore germination, while maintaining low cytotoxicity against mammalian cells, making them prime candidates for development into novel antifungal therapeutics.

microbiology↗